Last week, you might have seen that Metropolis Healthcare Limited (NSE:METROPOLIS) released its quarterly result to the market. The early response was not positive, with shares down 3.5% to ₹565 in the past week. The result was positive overall - although revenues of ₹4.5b were in line with what the analysts predicted, Metropolis Healthcare surprised by delivering a statutory profit of ₹2.73 per share, modestly greater than expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Taking into account the latest results, the current consensus from Metropolis Healthcare's 18 analysts is for revenues of ₹19.1b in 2027. This would reflect a notable 12% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to shoot up 27% to ₹12.32. Before this earnings report, the analysts had been forecasting revenues of ₹19.0b and earnings per share (EPS) of ₹12.23 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
View our latest analysis for Metropolis Healthcare
There were no changes to revenue or earnings estimates or the price target of ₹645, suggesting that the company has met expectations in its recent result. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Metropolis Healthcare analyst has a price target of ₹760 per share, while the most pessimistic values it at ₹500. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Metropolis Healthcare shareholders.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Metropolis Healthcare's past performance and to peers in the same industry. The analysts are definitely expecting Metropolis Healthcare's growth to accelerate, with the forecast 16% annualised growth to the end of 2027 ranking favourably alongside historical growth of 6.9% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 18% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Metropolis Healthcare is expected to grow at about the same rate as the wider industry.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target held steady at ₹645, with the latest estimates not enough to have an impact on their price targets.
With that in mind, we wouldn't be too quick to come to a conclusion on Metropolis Healthcare. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Metropolis Healthcare going out to 2029, and you can see them free on our platform here..
And what about risks? Every company has them, and we've spotted 1 warning sign for Metropolis Healthcare you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.